What is Biorep Technologies?
Founded in 1994 as a privately owned family business, Biorep Technologies, Inc. has dedicated over 25 years to the development of medical products. The company's mission is intrinsically linked to supporting research efforts for a biological cure for type I diabetes, notably through its collaboration with the Diabetes Research Institute (DRI). As a full-service development firm, Biorep's expertise is concentrated on medical devices, and it operates with ISO 13485 certification and FDA registration, signifying a commitment to stringent quality and regulatory standards in its specialized field.
How much funding has Biorep Technologies raised?
Biorep Technologies has raised a total of $630K across 2 funding rounds:
Debt
$350K
Debt
$280K
Debt (2020): $350K with participation from PPP
Debt (2021): $280K led by PPP
Key Investors in Biorep Technologies
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Biorep Technologies?
The recent major strategic investment signals a pivotal phase for Biorep Technologies, likely enabling the company to accelerate its product development pipeline and expand its market reach. Given its long-standing focus on medical devices and its mission-driven approach to diabetes research, this capital infusion is expected to fuel innovation and potentially lead to the commercialization of new technologies aimed at improving patient outcomes. The company's enterprise-level funding context suggests a trajectory towards scaling operations and solidifying its position as a key player in the medical technology landscape.
See full Biorep Technologies company page
